Citius Pharmaceuticals is trading 5.4% up at $0.76, with no fresh company-specific announcement identified to explain the advance.
- The move extends from the $0.72 close on August 11, 2026.
- The latest notable catalyst remains August 5, 2026 reporting of strong LYMPHIR launch momentum, including increased treatment-center and wholesaler uptake; it is not sufficiently current to establish direct causation.
- Nasdaq is up 0.60%, providing a supportive risk-on backdrop; confidence is low without a direct catalyst or volume data.